HRP20160103T1 - Paraziticidne formulacije za injektiranje od levamisola i makrocikliäśkih laktona - Google Patents
Paraziticidne formulacije za injektiranje od levamisola i makrocikliäśkih laktona Download PDFInfo
- Publication number
- HRP20160103T1 HRP20160103T1 HRP20160103TT HRP20160103T HRP20160103T1 HR P20160103 T1 HRP20160103 T1 HR P20160103T1 HR P20160103T T HRP20160103T T HR P20160103TT HR P20160103 T HRP20160103 T HR P20160103T HR P20160103 T1 HRP20160103 T1 HR P20160103T1
- Authority
- HR
- Croatia
- Prior art keywords
- levamisole
- formulation
- volume
- concentration
- mass
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 23
- 238000009472 formulation Methods 0.000 title claims 20
- 229960001614 levamisole Drugs 0.000 title claims 12
- 150000002596 lactones Chemical class 0.000 title claims 11
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 title claims 10
- 230000000590 parasiticidal effect Effects 0.000 title 1
- 239000004094 surface-active agent Substances 0.000 claims 10
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 9
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims 8
- 229960002346 eprinomectin Drugs 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical group CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- UXCQPEDHCCJBNL-UHFFFAOYSA-N 1-[(4-fluorophenyl)-isocyanomethyl]sulfonyl-4-methylbenzene Chemical group C1=CC(C)=CC=C1S(=O)(=O)C([N+]#[C-])C1=CC=C(F)C=C1 UXCQPEDHCCJBNL-UHFFFAOYSA-N 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 229960000283 levamisole phosphate Drugs 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000008215 water for injection Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 244000000013 helminth Species 0.000 claims 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 2
- 229960002216 methylparaben Drugs 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims 1
- 241000244206 Nematoda Species 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 241000869417 Trematodes Species 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 229960002418 ivermectin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Farmaceutska ili veterinarski prihvatljiva formulacija, naznačena time, da je prilagođena za ubrizgavanje u životinju, pri čemu ta formulacija obuhvaća sljedeće:
a. učinkovitu količinu levamisola;
b. učinkovitu količinu najmanje jednog makrocikličkog laktona;
c. farmaceutski prihvatljiv sustav otapala i tenzida, dok taj sustav doprinosi prihvatljivoj stabilnosti kod skladištenja oba sredstva – levamisola i makrocikličkog laktona, te pritom sustav doprinosi viskozitetu koji je prikladan za injekciju;
pri čemu sustav sadrži najmanje jedan tenzid, dok tenzid je CREMOPHOR EL, i organsko otapalo koje se može miješati s vodom, a to je dimetilacetamid (DMA).
2. Formulacija prema zahtjevu 1, naznačena time, da levamisol je levamisol-fosfat i pritom je levamisol prisutan u količini dovoljnoj za pripravu doze od najmanje 4 mg/kg prema masi životinje.
3. Formulacija prema zahtjevu 1, naznačena time, da makrociklički lakton je bilo ivermektin ili eprinomektin, i prisutan je u količini dovoljnoj za pripravu doze od najmanje 150 μg/kg prema masi životinje.
4. Formulacija prema bilo kojem od zahtjeva 1 ili 3, naznačena time, da nadalje obuhvaća antioksidant, konzervans i vodu za injekciju, pri čemu se voda za injekciju dobavlja u količini dovoljnoj za dovođenje formulacije u prikladan volumen za ubrizgavanje.
5. Formulacija prema bilo kojem od zahtjeva 1 do 4, naznačena time, da je koncentracija makrocikličkog laktona od oko 0,1 % do oko 2% (masa/volumen); koncentracija levamisola je od oko 15% do oko 30% (masa/volumen); i koncentracija tenzida je od oko 1% do oko 10% (masa/volumen).
6. Formulacija prema zahtjevu 5, naznačena time, da makrociklički lakton je eprinomektin i njegova koncentracija je od oko 0,5% do oko 0,9% (masa/volumen); levamisol je levamisol-fosfat i njegova koncentracija je od oko 18% do oko 25% (masa/volumen); tenzid je CREMOPHOR EL ili je kombinacija od sredstava CREMOPHOR EL i POLYSORBAT 80, i njihova koncentracija je od oko 3% do oko 7% (masa/volumen); antioksidant je BHT; otapalo je DMA i njegova koncentracija je od oko 1% do oko 10% (masa/volumen); a konzervans je metilparaben.
7. Formulacija prema bilo kojem od zahtjeva 1 do 6, naznačena time, da makrociklički lakton je eprinomektin i pritom eprinomektin ima takvo svojstvo, da njegov sadržaj B1a je veći ili jednak 85% i njegov sadržaj B1a + B1b je veći ili jednak 90%; te time da je gustoća formulacije između 0,95 i 1,20, a pH-vrijednost je između 3,0 i 5,0.
8. Farmaceutska ili veterinarski prihvatljiva formulacija koja je prilagođena za ubrizgavanje u životinju, naznačena time, da formulacija obuhvaća sljedeće:
a. učinkovitu količinu levamisola;
b. učinkovitu količinu najmanje jednog makrocikličkog laktona;
c. farmaceutski prihvatljiv sustav otapala i tenzida, dok taj sustav doprinosi prihvatljivoj stabilnosti kod skladištenja za oba sredstva – levamisol i makrociklički lakton, te pritom sustav doprinosi viskozitetu koji je prikladan za injekciju;
pri čemu sustav sadrži najmanje jedan tenzid, dok tenzid je CREMOPHOR EL, i organsko otapalo koje se može miješati s vodom, a to je dimetilacetamid (DMA),
dok makrociklički lakton je eprinomektin i njegova koncentracija je od oko 0,5% do oko 0,9% (masa/volumen); levamisol je levamisol-fosfat i njegova koncentracija je od oko 18% do oko 25% (masa/volumen); tenzid je POLYSORBAT 80, CREMOPHOR EL ili njihova kombinacija, i njihova koncentracija je od oko 3% do oko 7% (masa/volumen); antioksidant je BHT; otapalo je DMA i njegova koncentracija je od oko 1% do oko 10% (masa/volumen); a konzervans je metilparaben.
9. Formulacija prema bilo kojem od zahtjeva 1 do 8, naznačena time, da se upotrebljava u prevenciji ili liječenju unutrašnjih učestalih parazitnih zaraza kod životinja.
10. Formulacija za uporabu prema zahtjevu 9, naznačena time, da se formulacija ubrizgava injekcijom.
11. Formulacija za uporabu prema zahtjevu 9 ili 10, naznačena time, da je koncentracija makrocikličkog laktona od 0,5% do 0,9% (masa/volumen) i koncentracija levamisola je od 15% do 25% (masa/volumen).
12. Formulacija za uporabu prema zahtjevu 9 ili 10, naznačena time, da paraziti su helminti.
13. Formulacija za uporabu prema zahtjevu 12, naznačena time, da helminti su nematodi, cestodi, trematodi.
14. Postupak za proizvodnju formulacije prema zahtjevu 1 ili 2, naznačen time, da obuhvaća sljedeće korake:
a. dodavanje vode u posudu za injekciju;
b. otapanje levamisola u vodi;
c. otapanje eprinomektina i BHT u DMA u odvojenoj posudi;
d. dodavanje tenzida u smjesu od DMA i eprinomektina;
e. prijenos smjese od DMA i eprinomektina u cijelu masu vodene faze uz miješanje; i
f. opcijski, dovođenje smjese za punjenje do željenog volumena za ubrizgavanje, dodavanjem vode za injekciju uz miješanje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33388210P | 2010-05-12 | 2010-05-12 | |
| PCT/US2011/036321 WO2011143479A1 (en) | 2010-05-12 | 2011-05-12 | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
| EP11731566.3A EP2568980B1 (en) | 2010-05-12 | 2011-05-12 | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160103T1 true HRP20160103T1 (hr) | 2016-02-26 |
Family
ID=44342950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160103TT HRP20160103T1 (hr) | 2010-05-12 | 2016-01-29 | Paraziticidne formulacije za injektiranje od levamisola i makrocikliäśkih laktona |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110281920A1 (hr) |
| EP (1) | EP2568980B1 (hr) |
| AR (1) | AR081187A1 (hr) |
| AU (1) | AU2011252987B2 (hr) |
| DK (1) | DK2568980T3 (hr) |
| ES (1) | ES2554245T3 (hr) |
| HR (1) | HRP20160103T1 (hr) |
| HU (1) | HUE028600T2 (hr) |
| NZ (1) | NZ603699A (hr) |
| PL (1) | PL2568980T3 (hr) |
| PT (1) | PT2568980E (hr) |
| SI (1) | SI2568980T1 (hr) |
| WO (1) | WO2011143479A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010101389C4 (en) * | 2010-12-08 | 2017-03-02 | Jurox Pty Ltd | Anthelmintic formulation |
| UA113179C2 (xx) | 2011-06-23 | 2016-12-26 | Антипаразитарна композиція, яка містить макроциклічний лактон і левамізол, і спосіб лікування паразитарної інфестації | |
| NZ594610A (en) * | 2011-08-16 | 2013-03-28 | Virbac New Zealand Ltd | Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants |
| US20140045885A1 (en) * | 2012-08-10 | 2014-02-13 | Siobhan P. Ellison | Decoquinate, 4-hydroxyquinolones and napthoquinones combined with levamisole, Imidazothiazole, for the prevention and treatment of sarcocystosis and equine protozoal myeloencephalitis caused by Sarcocystis and Neospora and other apicomplexan protozoans. |
| RU2527329C2 (ru) * | 2012-10-25 | 2014-08-27 | Государственное научное учреждение Курский научно-исследовательский институт агропромышленного производства Россельхозакадемии | Способ получения комплексного иммунометаболического препарата с антиинфекционной активностью |
| WO2014098623A1 (en) * | 2012-12-20 | 2014-06-26 | Alleva Animal Health Limited | Injectable eprinomectin formulation and anthelmintic use thereof |
| ES2846820T3 (es) | 2013-04-12 | 2021-07-29 | Zoetis Services Llc | Composición de lactonas macrocíclicas, levamisol, un aminoazúcar y un agente antiparasitario adicional |
| BR102013031277B1 (pt) * | 2013-12-05 | 2018-10-02 | Ouro Fino Participacoes E Empreendimentos S A | processo para preparar uma suspensão anti-helmíntica e suspensão anti-helmíntica injetável |
| AU2016200283B2 (en) * | 2015-02-21 | 2016-10-13 | Al Hanbali, Othman Abdul Rahim DR | LEVIA: A New Injectable Parasiticidal Veterinary Formulation of Levamisole HCI and Ivermectin Solution |
| WO2018038623A1 (en) * | 2016-08-23 | 2018-03-01 | Donaghys Limited | Improvements in parasite treatments |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950360A (en) | 1972-06-08 | 1976-04-13 | Sankyo Company Limited | Antibiotic substances |
| SE434277B (sv) | 1976-04-19 | 1984-07-16 | Merck & Co Inc | Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis |
| US4096271A (en) * | 1977-08-03 | 1978-06-20 | American Cyanamid Company | Slow release injectable formulations of tetramisole and derivatives in benzyl benzoate |
| US4199569A (en) | 1977-10-03 | 1980-04-22 | Merck & Co., Inc. | Selective hydrogenation products of C-076 compounds and derivatives thereof |
| US4389397A (en) * | 1980-08-04 | 1983-06-21 | Merck & Co., Inc. | Solubilization of ivermectin in water |
| US4427663A (en) | 1982-03-16 | 1984-01-24 | Merck & Co., Inc. | 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof |
| EP0237482A1 (de) | 1986-03-06 | 1987-09-16 | Ciba-Geigy Ag | C(29)-Carbonyloxi-milbemycin-Derivate zur Bekämpfung von tier- und pflanzenparasitären Schädlingen |
| DE3767560D1 (de) | 1986-03-25 | 1991-02-28 | Sankyo Co | Makrolide verbindungen, ihre herstellung und verwendung. |
| ATE75745T1 (de) | 1986-07-02 | 1992-05-15 | Ciba Geigy Ag | Pestizide. |
| US4855317A (en) | 1987-03-06 | 1989-08-08 | Ciba-Geigy Corporation | Insecticides and parasiticides |
| US4871719A (en) | 1987-03-24 | 1989-10-03 | Ciba-Geigy Corporation | Composition for controlling parasites in productive livestock |
| US4874749A (en) | 1987-07-31 | 1989-10-17 | Merck & Co., Inc. | 4"-Deoxy-4-N-methylamino avermectin Bla/Blb |
| EP0319142B1 (en) | 1987-11-03 | 1994-04-06 | Beecham Group Plc | Intermediates for the preparation of anthelmintic macrolide antibiotics |
| NZ232422A (en) | 1989-02-16 | 1992-11-25 | Merck & Co Inc | 13-ketal milbemycin derivatives and parasiticides |
| US5602107A (en) | 1993-05-10 | 1997-02-11 | Merck & Co., Inc. | Pour-on formulations consisting of gylcols, glycerides and avermectin compounds |
| US6733767B2 (en) | 1998-03-19 | 2004-05-11 | Merck & Co., Inc. | Liquid polymeric compositions for controlled release of bioactive substances |
| US6174540B1 (en) | 1998-09-14 | 2001-01-16 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated caster oil |
| WO2000074489A1 (en) * | 1999-06-04 | 2000-12-14 | Nufarm Limited | Stable biocidal compositions |
| EG23124A (en) | 2001-02-27 | 2004-04-28 | Syngenta Participations Ag | Avermectins substituted in the 4-position having pesticidal properties |
| CR6574A (es) | 2001-02-27 | 2004-10-28 | Syngenta Participations Ag | Sales de avermectinas substituidas en la posicion 4 con propiedades plaguicidas |
| AR036486A1 (es) | 2001-08-28 | 2004-09-15 | Syngenta Participations Ag | Derivados 4"-desoxi-4"-(s)-amino avermectina, composicion plaguicida, procedimiento para la preparacion de esa composicion, metodo para controlar plagas, y uso de estos derivados para preparar una composicion |
| AR037938A1 (es) | 2001-12-21 | 2004-12-22 | Syngenta Participations Ag | Derivados de avermectina b1 que tienen un substituyente de aminosulfoniloxilo en la posicion 4'' |
| NZ520295A (en) * | 2002-07-19 | 2005-04-29 | Ashmont Holdings Ltd | Anthelmintic formulations comprising levamisole and either an avermectin or milbemycin |
| AU2002952597A0 (en) * | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
| GB0302308D0 (en) | 2003-01-31 | 2003-03-05 | Syngenta Participations Ag | Avermectin and avermectin monosaccharide derivatives substituted in the 4"- or 4'-position having pesticidal properties |
| GB0302310D0 (en) | 2003-01-31 | 2003-03-05 | Syngenta Participations Ag | Avermectin- and avermectin monosaccharide derivatives substituted in the 4"- or 4' - positionhaving pesticidal properties |
| AU2003900505A0 (en) * | 2003-02-05 | 2003-02-20 | Jurox Pty Ltd | Anthelmintic composition |
| GB0313937D0 (en) | 2003-06-16 | 2003-07-23 | Syngenta Participations Ag | Avermectin B1 monosaccharide derivatives having an aminosulfonyloxy substituentin the 4'-position |
| GB0320176D0 (en) | 2003-08-28 | 2003-10-01 | Syngenta Participations Ag | Avermectins and avermectin monosaccharides substitued in the 4'-and 4"-positionhaving pesticidal properties |
| US8697031B2 (en) * | 2004-06-04 | 2014-04-15 | Case Western Reserve University | Dual function polymer micelles |
| CN101065352A (zh) * | 2004-09-23 | 2007-10-31 | 先灵-普劳有限公司 | 使用新的三氟甲磺酰苯胺肟醚衍生物控制动物中的寄生虫 |
| BRPI0506279B1 (pt) * | 2005-12-16 | 2018-01-09 | Npa - Núcleo De Pesquisas Aplicadas Ltda | Composição sinergística de antihelmínticos e endectocidas |
| EP1968579A1 (en) * | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2362774A1 (en) | 2008-08-18 | 2011-09-07 | Intervet International BV | Anthelmintic compositions |
| US8313752B2 (en) * | 2009-04-14 | 2012-11-20 | Merial Limited | Macrocyclic lactone combination compositions, vaccines and methods for producing same |
-
2011
- 2011-05-12 EP EP11731566.3A patent/EP2568980B1/en active Active
- 2011-05-12 DK DK11731566.3T patent/DK2568980T3/en active
- 2011-05-12 NZ NZ603699A patent/NZ603699A/xx unknown
- 2011-05-12 PT PT117315663T patent/PT2568980E/pt unknown
- 2011-05-12 US US13/106,677 patent/US20110281920A1/en not_active Abandoned
- 2011-05-12 ES ES11731566.3T patent/ES2554245T3/es active Active
- 2011-05-12 WO PCT/US2011/036321 patent/WO2011143479A1/en active Application Filing
- 2011-05-12 HU HUE11731566A patent/HUE028600T2/en unknown
- 2011-05-12 PL PL11731566T patent/PL2568980T3/pl unknown
- 2011-05-12 AU AU2011252987A patent/AU2011252987B2/en active Active
- 2011-05-12 AR ARP110101654A patent/AR081187A1/es unknown
- 2011-05-12 SI SI201130720T patent/SI2568980T1/sl unknown
-
2016
- 2016-01-29 HR HRP20160103TT patent/HRP20160103T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR081187A1 (es) | 2012-07-04 |
| ES2554245T3 (es) | 2015-12-17 |
| WO2011143479A1 (en) | 2011-11-17 |
| EP2568980B1 (en) | 2015-11-11 |
| NZ603699A (en) | 2013-08-30 |
| AU2011252987A1 (en) | 2012-12-13 |
| US20110281920A1 (en) | 2011-11-17 |
| HUE028600T2 (en) | 2016-12-28 |
| EP2568980A1 (en) | 2013-03-20 |
| PT2568980E (pt) | 2016-03-15 |
| PL2568980T3 (pl) | 2016-05-31 |
| SI2568980T1 (sl) | 2016-02-29 |
| AU2011252987B2 (en) | 2013-05-02 |
| DK2568980T3 (en) | 2015-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160103T1 (hr) | Paraziticidne formulacije za injektiranje od levamisola i makrocikliäśkih laktona | |
| JP6946528B2 (ja) | イソオキサゾリン活性薬を含む殺寄生虫性組成物、その方法および使用 | |
| AU2008329706B2 (en) | Solvent systems for pour-on formulations for combating parasites | |
| ES2385126T3 (es) | Pasta antihelmíntica que comprende praziquantel, una lactona macrolida, ciclodextrina y un espesante | |
| SA518391187B1 (ar) | طرق لإنتاج صيغ علاجية ثابتة في مذيبات قطبية لا بروتونية | |
| CN107427496A (zh) | 包含异噁唑啉活性剂的长效可注射配制剂、其方法和用途 | |
| CN104202985A (zh) | 包含氟虫腈和氯菊酯的局部组合物和使用方法发明领域 | |
| CN106132409A (zh) | 稳定的兽用驱虫制剂 | |
| WO2013043064A1 (en) | Veterinary anthelmintic delivery system | |
| WO2021013825A1 (en) | Soft chewable veterinary dosage form | |
| KR20080073700A (ko) | 벤즈이미다졸 비수성 조성물 | |
| CN102176899B (zh) | 苯并咪唑驱虫药组合物 | |
| AU2011268899B2 (en) | Injectable formulation of a macrocyclic lactone and levamisole | |
| CN104083324B (zh) | 一种利福昔明的兽用悬乳剂及其制备方法和应用 | |
| AU2013205280A1 (en) | Macrocyclic Lactone injectable Formulations | |
| CA2673193C (en) | Homogeneous paste and gel formulations | |
| RU2020119425A (ru) | Составы на основе пептидов с длительным высвобождением | |
| NZ548938A (en) | Topical macrocyclic lactone formulation | |
| NZ594610A (en) | Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants | |
| AU2013201461A1 (en) | Solvent systems for pour-on formulations for combating parasites | |
| ES2416004B1 (es) | Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales. | |
| EP4230203A1 (en) | Microsuspension against parasites and method for obtaining same | |
| BR112016020896B1 (pt) | Formulações anti-helmínticas veterinárias estáveis |